Clinical Trial Highlights

Upgraded FY 2023 guidance IPSEN Innovation for patient care Γ Total-sales growth greater than 6.0% at constant exchange rates Γ Core operating margin greater than 30.0% of total sales Expected adverse impact of around 3% from currencies, based on average level of exchange rates in June 2023 Excludes any potential impact of incremental investments from external-innovation transactions 15

View entire presentation